Lymphoma, Non-Hodgkin; Sex-specific Differences
Lymphoid malignancies particularly of the B-cell type are among the most common malignancies in Western countries. They are also characterized by a male preponderance and a more benevolent disease course in women. We try to elucidate the bases of these sex-specific differences which not only seem to have an impact on the molecular characteristics of the malignant cells but also on clinical presentation and response to treatment.
- Allain, E.P. et al., 2019. Inactivation of Prostaglandin E2 as a Mechanism for UGT2B17-Mediated Adverse Effects in Chronic Lymphocytic Leukemia. Frontiers in Oncology, 9. Available at: http://dx.doi.org/10.3389/fonc.2019.00606.
- Allain, E.P. et al., 2018. Sex-dependent association of circulating sex steroids and pituitary hormones with treatment-free survival in chronic lymphocytic leukemia patients. Annals of Hematology, 97(9), pp.1649–1661. Available at: http://dx.doi.org/10.1007/s00277-018-3356-z.
- Freund, P. et al., 2016. Cannabinoid Receptors Are Overexpressed in CLL but of Limited Potential for Therapeutic Exploitation G. Velasco, ed. PLOS ONE, 11(6), p.e0156693. Available at: http://dx.doi.org/10.1371/journal.pone.0156693.
- Brunhofer-Bolzer, G. et al., 2015. SAR-Guided Development and Characterization of a Potent Antitumor Compound toward B-Cell Neoplasms with No Detectable Cytotoxicity toward Healthy Cells. Journal of Medicinal Chemistry, 58(3), pp.1244–1253. Available at: http://dx.doi.org/10.1021/jm501848m.
- Porpaczy, E. et al., 2013. Lipoprotein lipase in chronic lymphocytic leukaemia – Strong biomarker with lack of functional significance. Leukemia Research, 37(6), pp.631–636. Available at: http://dx.doi.org/10.1016/j.leukres.2013.02.008.